JP2023543211A - 徐放性医薬製剤 - Google Patents

徐放性医薬製剤 Download PDF

Info

Publication number
JP2023543211A
JP2023543211A JP2023518735A JP2023518735A JP2023543211A JP 2023543211 A JP2023543211 A JP 2023543211A JP 2023518735 A JP2023518735 A JP 2023518735A JP 2023518735 A JP2023518735 A JP 2023518735A JP 2023543211 A JP2023543211 A JP 2023543211A
Authority
JP
Japan
Prior art keywords
ketamine
tablet
active agent
molecular weight
norketamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543211A5 (https=
Inventor
ウィリアム グルー，ポール
ジューン メドリコット，ナタリー
ウィリアム サーマン，ピーター
ロン，ユエフォン
Original Assignee
ダグラス ファーマシューティカルズ エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/030,705 external-priority patent/US12090123B2/en
Application filed by ダグラス ファーマシューティカルズ エルティーディー． filed Critical ダグラス ファーマシューティカルズ エルティーディー．
Publication of JP2023543211A publication Critical patent/JP2023543211A/ja
Publication of JP2023543211A5 publication Critical patent/JP2023543211A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2023518735A 2020-09-24 2021-09-22 徐放性医薬製剤 Pending JP2023543211A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/030,705 2020-09-24
US17/030,705 US12090123B2 (en) 2017-10-10 2020-09-24 Extended release pharmaceutical formulation
PCT/IB2021/058647 WO2022064387A1 (en) 2020-09-24 2021-09-22 Extended release pharmaceutical formulation

Publications (2)

Publication Number Publication Date
JP2023543211A true JP2023543211A (ja) 2023-10-13
JP2023543211A5 JP2023543211A5 (https=) 2024-10-01

Family

ID=80846364

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518735A Pending JP2023543211A (ja) 2020-09-24 2021-09-22 徐放性医薬製剤

Country Status (9)

Country Link
US (1) US20250049734A1 (https=)
EP (1) EP4216937A4 (https=)
JP (1) JP2023543211A (https=)
KR (1) KR20230074522A (https=)
CN (1) CN116456972A (https=)
AU (1) AU2021350581A1 (https=)
CA (1) CA3190204A1 (https=)
MX (1) MX2023003369A (https=)
WO (1) WO2022064387A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10869838B2 (en) * 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
WO2024171074A1 (en) * 2023-02-15 2024-08-22 Clearmind Medicine Inc. Compositions comprising ketamine, optionally in combination with n-acylethanolamines, and uses thereof
WO2025099182A1 (en) * 2023-11-07 2025-05-15 HMNC Holding GmbH Induction regime for the administration of 2-(2-chlorphenyl)-2-(methylamino) cyclohexan-1-one
WO2025099181A1 (en) * 2023-11-07 2025-05-15 HMNC Holding GmbH Maintenance regime for the administration of 2-(2-chlorphenyl)-2-(methylamino) cyclohexan-1-one

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019073408A1 (en) * 2017-10-10 2019-04-18 Douglas Pharmaceuticals Ltd. PROLONGED RELEASE PHARMACEUTICAL FORMULATION AND TREATMENT METHODS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2922507C (en) * 2013-08-26 2022-07-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
DK3215147T3 (da) * 2014-11-04 2024-04-02 Acadia Pharm Inc Neurodæmpende norketamin-forbindelser og fremgangsmåder
US10441544B2 (en) * 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019073408A1 (en) * 2017-10-10 2019-04-18 Douglas Pharmaceuticals Ltd. PROLONGED RELEASE PHARMACEUTICAL FORMULATION AND TREATMENT METHODS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, vol. 10, JPN6025034994, May 2020 (2020-05-01), pages 1 - 6, ISSN: 0005775068 *

Also Published As

Publication number Publication date
EP4216937A4 (en) 2024-09-04
WO2022064387A1 (en) 2022-03-31
CA3190204A1 (en) 2022-03-31
EP4216937A1 (en) 2023-08-02
MX2023003369A (es) 2023-08-14
KR20230074522A (ko) 2023-05-30
US20250049734A1 (en) 2025-02-13
AU2021350581A1 (en) 2023-03-23
CN116456972A (zh) 2023-07-18

Similar Documents

Publication Publication Date Title
US11045424B2 (en) Extended release pharmaceutical formulation
US12350378B2 (en) Extended release pharmaceutical formulation and methods of treatment
US12472146B2 (en) Extended release pharmaceutical formulation
US11471416B2 (en) Extended release pharmaceutical formulation and methods of treatment
US12611386B2 (en) Extended release pharmaceutical formulation
US20250049734A1 (en) Extended release pharmaceutical formulation
US20260034065A1 (en) Extended release pharmaceutical formulation
HK40088923A (zh) 延长释放的药物制剂
HK40066605A (en) Extended release pharmaceutical formulation
HK40066605B (en) Extended release pharmaceutical formulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240920

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20260209

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260210

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20260210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260407